During the past decade, Medical oncology department, University Hospital, Tours conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Medical oncology department, University Hospital, Tours" are "Bladder Cancer" (1 trials), "ENT Cancer" (1 trials), "Kidney Cancer" (1 trials), "Lung Cancer" (1 trials) and "Lupus Erythematosus, Systemic" (1 trials). Many other conditions were trialed in "Medical oncology department, University Hospital, Tours" in a lesser frequency.

Most popular intervention types in "Medical oncology department, University Hospital, Tours" are "Other" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Blood samples" (3 trials) and "Pharmacokinetic of Nivolumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Medical oncology department, University Hospital, Tours" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Medical oncology department, University Hospital, Tours". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Medical oncology department, University Hospital, Tours, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Medical oncology department, University Hospital, Tours, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".